Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Am J Clin Pathol. 2012 Jan;137(1):93-100. doi: 10.1309/AJCP59UORCYZEVQO.
The membrane glycoprotein MRC OX-2 (CD200) is expressed in several lymphoid malignancies. However, the diagnostic usefulness and potential prognostic importance of CD200 expression have not been rigorously examined. We show that CD200 is uniformly expressed in chronic lymphocytic leukemia (CLL) and absent in mantle cell lymphoma (MCL). It is important to note that expression of CD200 is retained even in CLLs with immunophenotypic aberrancies, making CD200 a particularly useful marker for discrimination between these cases and MCL. CD200 is expressed in nearly all precursor B-lymphoblastic leukemias, with aberrant overexpression or underexpression compared with normal B-cell progenitors in 55% of cases. More than 70% of plasma cell myelomas (PCMs) expressed CD200, and loss of CD200 expression in PCM may be associated with more clinically aggressive disease. CD200 is expressed in several hematolymphoid neoplasms. Analysis of its expression has several diagnostic and potentially prognostic applications in the flow cytometric evaluation of lymphoid malignancies.
膜糖蛋白 MRC OX-2（CD200）在几种淋巴恶性肿瘤中表达。然而，CD200 表达的诊断有用性和潜在预后意义尚未经过严格检查。我们表明 CD200 在慢性淋巴细胞白血病（CLL）中均匀表达，而在套细胞淋巴瘤（MCL）中缺失。需要注意的是，即使在具有免疫表型异常的 CLL 中，CD200 的表达也保留下来，这使得 CD200 成为区分这些病例和 MCL 的特别有用的标志物。CD200 在几乎所有前体 B 淋巴细胞白血病中表达，与正常 B 细胞前体相比，在 55%的病例中过度表达或表达不足。超过 70%的浆细胞瘤（PCM）表达 CD200，PCM 中 CD200 的表达丧失可能与更具临床侵袭性的疾病相关。CD200 在几种血液淋巴肿瘤中表达。分析其表达在流式细胞术评估淋巴恶性肿瘤时有几个诊断和潜在的预后应用。
